The possible role of F-18 FDG positron emission tomography in the differential diagnosis of focal pancreatic lesions

Clinical Nuclear Medicine

Volumn 27, Issue 3, 2002, Pages 197-201

  Papós, Miklós ^a   Takács, Tamás ^a   Trón, Lajos ^c   Farkas, Gyula ^b   Ambrus, Edit ^a   Szakáll Jr , Szabolcs ^c   Lonovics, János ^a   Csernay, László ^a   Pávics, László ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b UNIVERSITY OF SZEGED   (Hungary)

^c UNIVERSITY OF DEBRECEN   (Hungary)

Author keywords

Computed Tomography; Endoscopic Retrograde Cholangiopancreatography; F 18 Fluorodeoxyglucose Positron Emission Tomography; Pancreatic Carcinoma; Ultrasound

Indexed keywords

CA 19-9 ANTIGEN; FLUORODEOXYGLUCOSE F 18;

ADULT; ARTICLE; CANCER DIAGNOSIS; CLINICAL ARTICLE; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; ENDOSCOPIC RETROGRADE CHOLANGIOPANCREATOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; PANCREAS CARCINOMA; PANCREAS TUMOR; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; ULTRASOUND;

ADULT; CA-19-9 ANTIGEN; CHOLANGIOPANCREATOGRAPHY, ENDOSCOPIC RETROGRADE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY;

EID: 0036192410     PISSN: 03639762     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003072-200203000-00010     Document Type: Article

References (27)

1. Pancreatic cancer. A continuing diagnostic dilemma
2. Epidemiology and etiology of pancreatic cancer
3. Pancreatic tumors: Imaging with PET
4. Pancreatic adenocarcinoma: CT versus MR imaging in the evaluation of resectability. Report of the Radiology Diagnostic Oncology Group
5. Diagnosis of pancreatic carcinoma
6. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: Comparison with CT, US
7. Diagnostic yield of endoscopic retrograde cholangiopancreatography in carcinoma of the pancreas
8. Carcinoma of the head of the pancreas. Therapeutical implications of endoscopic retrograde cholangiography findings
9. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from pancreatitis
10. PET with fluorine 18 deoxyglucose for pancreatic disease
11. Endoscopy retrograde cholangiopancreatography
12. Pancreatic carcinoma: Diagnosis and treatment
13. Value of ultrasonographic examination combined with measurement of serum tumour markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter
14. A prospective evaluation of computed tomography and ultrasound of the pancreas
15. Dynamic CT of pancreatic tumors
16. Initial clinical evaluation of an immunometric assay for CA 19-9 using the NCL serum bank
17. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies
18. Radical pancreatectomy for ductal cell carcinoma of the head of the pancreas
19. Endoscopic retrograde cholangiopancreatography in pancreatic diagnosis
20. Compartive clinical impact of endoscopic pancreatography gray-scale ultrasonography (EMI scanning) in pancreatic disease: Preliminary report
21. F-18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer
22. Diagnosis of pancreatic cancer by 2[18F]-fluoro-2-deoxy-D-glucose positron emission tomography
23. Superimposition of PET images using 18F-fluorodeoxyglucose with magnetic resonance images in patients with pancreatic carcinoma
24. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: High accumulation in macrophages and granulocytes studied microautoradiography
25. Fluorine 18-deoxyglucose and false-positive results: A major problem in the diagnostical oncological patients
26. Optimal interpretation of FDG PET in the diagnosis, staging and management of pancreatic carcinoma